MDGL (madrigalpharma.com) Market Value to Book Value Ratio

Official company branding of Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals (MDGL) possesses exceptional pricing power due to its first-mover advantage in MASH therapy. High clinical trial costs and patent protection create formidable barriers to entry for competitors. The company is tapping into a massive market for metabolic pathologies while maintaining a temporary monopoly. The dynamics of market capitalization relative to the balance sheet clearly demonstrate the current trend, with the value 19.60 capturing this metric.

MDGL Madrigal Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Madrigal Pharmaceuticals Inc (MDGL)

- price and consensus price forecast:
Price Chart Madrigal Pharmaceuticals|MDGL - Price Target Chart
- market capitalization data:
Market Value Madrigal Pharma|MDGL - Full Business Value
- book capitalization data:
Book Value per Share Madrigal Pharmaceuticals|MDGL - Accounting Value of Company|Market Capitalization to Book Value Ratio madrigalpharma.com|MDGL - Company Total Assets
- debt and liquidity data:
Debt to Equity Madrigal Pharmaceuticals|MDGL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Madrigal Pharma|MDGL - Company Total Debt|Debts to Book Capitalization Madrigal Pharma|MDGL - Company Long-Term Debts|Company Current Liabilities Madrigal Pharmaceuticals
Initial company analysis:Madrigal Pharmaceuticals - MDGL
Original product of Madrigal Pharma

Investors in Madrigal Pharmaceuticals (MDGL) face a choice between growth potential and the risk of overpaying for uncertain future earnings. The market-to-book premium captures the gap between the market price and tangible assets, reflecting the extent of expectations priced in for its first-mover status in liver therapy amid pressure from competing pharma behemoths.

Main competitors

Ascendis Pharma A/S (ASND) - Market Value to Book Value Ratio|CORT (corcept.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Rhythm Pharmaceuticals, Inc. RYTM|Market Capitalization to Net Assets Akero Therapeutics, Inc.|Metsera Corp (MTSR) - Market Capitalization to Book Value Ratio|Market Value to Book Value MoonLake Corp (MLTX)|Market Capitalization to Book Value Ratio CRNX (Crinetics Pharmaceuticals)|newamsterdampharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Soleno Therapeutics, Inc. (SLNO)|FOLD: Market Value to Book Value|ETNB (89bio Corp) - Market Value to Book Value Ratio|Agios Corp (AGIO) - Market Cap to Net Assets Ratio|GPCR (Structure Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio mimedx.com (MDXG)|Rezolute (RZLT) - Market Cap to Net Assets Ratio|Market Value to Book Value LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Market Capitalization to Book Value Ratio|sagimet.com (SGMT) - Market-to-Book Ratio|BIOA - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)